Keywords: Non-Proton, Metabolism, preclinical, animals, brain, spectroscopy, deuteriumDiffuse midline gliomas (DMGs) are lethal pediatric brain tumors. DMG patients are typically treated with radiation in combination with an experimental agent in clinical trials. ONC206 is a novel drug with promising efficacy in preclinical models. Successful clinical translation and deployment of ONC206 requires the identification of companion biomarkers of treatment response. Therefore, the goal of this study was to identify magnetic resonance spectroscopy (MRS)-detectable biomarkers of response to ONC206 in preclinical DMG models. Our studies identify a combination of 1H- and 2H-MRS-detectable biomarkers that serve as imaging biomarkers of early response to ONC206 in mice bearing intracranial DMG xenografts.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords